Long-term treatment for up to 12o weeks, with the investigational drug Ozanimod (RPC-1063), found to be effective and safe in patients [...]
Multiple sclerosis patients who start Rituxan (rituximab) treatment are three times more likely to have unchanged or improved brain-scan [...]
Older patients with secondary progressive multiple sclerosis (SPMS) as well as older relapsing patients whose MS has been inactive after [...]
Long-term therapy with Tysabri (natalizumab) significantly improved the mental state of people with secondary progressive multiple [...]
Patients must help develop new outcome measures of multiple sclerosis (MS), since they and healthcare providers may have differing [...]
Patients with relapsing-remitting multiple sclerosis (RRMS) regain part of their balance control after a single training session of [...]
Genentech has rolled out a website to connect multiple sclerosis (MS) patients and caregivers with resources that can help [...]
NEW ORLEANS — The Consortium of Multiple Sclerosis Centers (CMSC) annual meetings always aim to offer a multidisciplinary educational [...]
MS is sneaky. It is expert at evading detection and diagnosis, and often brings a host of invisible symptoms that may come and go at [...]
At the ongoing Annual Meeting of the Society for Clinical Trials that is being jointly held with the International Clinical Trials [...]